Evidence map›Paper›PMID 32169380›Full record

Trial reportThe Journal of allergy and clinical immunology2020

Nasal allergen challenge and environmental exposure chamber challenge: A randomized trial comparing clinical and biological responses to cat allergen.

David Larson, Piyush Patel, Anne Marie Salapatek, Peter Couroux, Don Whitehouse, Adela Pina, Jacqueline L Johnson, Michelle L Sever, Srinath Sanda, Julian Poyser and 12 more

Open access · greenAbstract readRandomized Controlled Trial
In one paragraph

Trial report in The Journal of allergy and clinical immunology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers.

0numbers the graph read from it
0cells of the map it votes in
26citing papers in PubMed
3.3field-weighted citation impact, top 7% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

26 citing papers in PubMed, 38 citations in OpenAlex.

  1. Trial
  2. Trial
  3. Trial
  4. Observational
  5. Article
  6. Article
  7. Characterizing the symptomatology and pathophysiology of allergic rhinitis using a nasal allergen challenge model - a subset of the allergic rhinitis microbiome study.Allergy, asthma, and clinical immunology : official journal of the Canadian Society of Allergy and Clinical Immunology · 2025
    Article
  8. Clinical validation of controlled exposure to cat dander in the Specialized Particulate Control Environmental Exposure Unit (SPaC-EEU).Allergy, asthma, and clinical immunology : official journal of the Canadian Society of Allergy and Clinical Immunology · 2025
    Article
  9. Article
  10. Article
  11. Review
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. [Research progress and clinical application of allergen nasal provocation test].Lin chuang er bi yan hou tou jing wai ke za zhi = Journal of clinical otorhinolaryngology head and neck surgery · 2023
    Review
  18. Article
  19. Review
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

22 authors at 9 institutions in 3 countries.

David LarsonThe Immune Tolerance Network, Bethesda, Md. Electronic address: dlarson@immunetolerance.org.
Piyush PatelInflamax Research Limited, DBA Cliantha Research, Mississauga, Canada.
Anne Marie SalapatekInflamax Research Limited, DBA Cliantha Research, Mississauga, Canada.
Peter CourouxInflamax Research Limited, DBA Cliantha Research, Mississauga, Canada.
Don WhitehouseImmune Tolerance Network, San Francisco, Calif.
Adela PinaRho Federal Systems Division, Durham, NC.
Jacqueline L JohnsonRho Federal Systems Division, Durham, NC.
Michelle L SeverRho Federal Systems Division, Durham, NC.
Srinath SandaImmune Tolerance Network, San Francisco, Calif.
Julian PoyserNational Institute of Allergy and Infectious Diseases, Bethesda, Md.
Theresa AllioNational Institute of Allergy and Infectious Diseases, Bethesda, Md.
Guy W ScaddingMRC and Asthma UK, Centre in Allergic Mechanisms of Asthma, London, United Kingdom.
Tielin QinThe Immune Tolerance Network, Bethesda, Md.
Mohamed H ShamjiMRC and Asthma UK, Centre in Allergic Mechanisms of Asthma, London, United Kingdom; Immunomodulation and Tolerance Group, Allergy and Clinical Immunology, Section of Inflammation Repair and Development, National Heart and Lung Institute, Imperial College London, London, United Kingdom.
William W KwokBenaroya Research Institute, Department of Translational Research, Seattle, Wash.
Eddie A JamesBenaroya Research Institute, Department of Translational Research, Seattle, Wash.
Deanna FrenchMcMaster University, Hamilton, Ontario, Canada.
Alina LelicHuman Immunology Testing Suite, McMaster University, Hamilton, Ontario, Canada.
Mark LarchéMcMaster University, Hamilton, Ontario, Canada; Divisions of Clinical Immunology & Allergy and Respirology, Department of Medicine, Firestone Institute of Respiratory Health, The Research Institute, St Joe's Hamilton, Hamilton, Canada.
Matthew C AltmanDepartment of Medicine, University of Washington, Seattle, Wash; Benaroya Research Institute, Systems Immunology Division, Seattle, Wash.
Alkis TogiasNational Institute of Allergy and Infectious Diseases, Bethesda, Md.
Stephen R DurhamMRC and Asthma UK, Centre in Allergic Mechanisms of Asthma, London, United Kingdom; Immunomodulation and Tolerance Group, Allergy and Clinical Immunology, Section of Inflammation Repair and Development, National Heart and Lung Institute, Imperial College London, London, United Kingdom.
Immune Tolerance Network · USAsthma UK · GBInflamax Research (Canada) · CANational Institute of Allergy and Infectious Diseases · USRho (United States) · USBenaroya Research InstituteMcMaster University · CAPopulation Health Research Institute · CAUniversity of Washington · US

Funding

Immune Tolerance Network UM1 2023 SupplementUM1AI109565 · NIAID · BENAROYA RESEARCH INST AT VIRGINIA MASON · PI Mark S Anderson, Jane Hoyt Buckner · 2014 to 2026
$451.6M
Transplantation GroupUM2AI117870 · NIAID · RHO FEDERAL SYSTEMS DIVISION, INC. · PI DAVID, GLORIA · 2015 to 2023
$208.1M
NIAID NIH HHS HHSN272200800029CNIAID NIH HHS UM1 AI109565NIAID NIH HHS UM2 AI117870
6 · The paper itself

Abstract

backgroundThe direct-instillation nasal allergen challenge (NAC) and the environmental exposure chamber (EEC) are 2 methods of conducting controlled allergen provocations. The clinical and biological comparability of these methods has not been thoroughly investigated.

objectiveWe sought to compare clinical and immunologic responses to cat allergen in NAC versus EEC.

methodsTwenty-four participants were randomized to receive either NAC followed by a 2-day challenge in an EEC or a 2-day challenge in an EEC followed by NAC. Challenges were separated by 28-day washout periods. We measured total nasal symptom scores, peak nasal inspiratory flow, nasal (0-8 hours) and serum cytokines, serum antibodies, peripheral blood antigen-specific T lymphocytes, and gene expression in nasal scrapings. The primary outcome was the total nasal symptom score area under the curve for the first 3 hours after allergen exposure in NAC or after initiation of exposure in EEC.

resultsBoth challenges increased IL-5 and IL-13 in nasal fluids and serum and resulted in altered nasal cell expression of gene modules related to mucosal biology and transcriptional regulation. Changes in gene modules, more so than cytokine measurements, showed significant associations with total nasal symptom score and peak nasal inspiratory flow. Overall, EEC exposure generated larger responses and more early terminations compared with NAC. Although the 2 challenges did not correlate in symptom magnitude or temporality, striking correlations were observed in cytokine levels.

conclusionsAlthough clinical outcomes of NAC and EEC were temporally different and nonequivalent in magnitude, immunologic responses were similar. Selection of a particular allergen challenge method should depend on considerations of study objectives and cost.

Indexed as

Administration, IntranasalAdultAllergensAnimalsAntibodiesCatsCytokinesEnvironmental ExposureFemaleHumansInhalationMaleMiddle AgedNasal MucosaNasal Provocation TestsSkin TestsAllergensAntibodiesCytokinescat allergycat danderenvironmental exposure chamberepitheliumFel d1Nasal allergen challengepeak nasal inspiratory flowtotal nasal symptom score

Identifiers

PMID32169380
PMCPMC8958045
OpenAlexW3012208294

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.